Browse by Audience
Chronic overlapping pain conditions (COPCs) are believed to share common etiological mechanisms involving central sensitization. Genetic and environmental factors putatively combine to influence susceptibility to central sensitization and COPCs. This […]
Learn More >Despite decreases in US opioid prescribing rates, daily morphine milligram equivalents (MME) prescribed per person remains three times higher than in 1999. An interprofessional team (IPT) was developed to support […]
Learn More >For many years triptans have been the cornerstone of acute migraine treatment. Nevertheless, treatment with triptans may not always be initiated due to contraindications (seen in approximately one fifth of […]
Learn More >Alopecia is associated with erenumab post-marketing, but no cases have been described.
Learn More >Greater occipital nerve blockade for the prevention of chronic migraine has a limited evidence base. A robust randomized double-blind, placebo-controlled trial is needed.
Learn More >This post-hoc analysis from three phase 3 treatment trials of rimegepant 75 mg – an oral small molecule calcitonin gene-related peptide receptor antagonist for acute and preventive treatment of migraine – […]
Learn More >To assess the efficacy of pain neuroscience education combined with physiotherapy for the management of migraine. Physiotherapy can significantly reduce the frequency of migraine, but the evidence is based only […]
Learn More >The lack of knowledge about the intra- and interindividual attack frequency variability in chronic cluster headache complicates power and sample size calculations for baseline periods of trials, and consensus on […]
Learn More >Long-term data helps assess the consistency of efficacy, tolerability, and safety of acute treatment over repeated use for different attacks. Real-world studies help assess tolerability, safety, and efficacy in patients […]
Learn More >Few therapeutic options are available for patients with moderate-to-severe hidradenitis suppurativa. We aimed to assess the efficacy of secukinumab in patients with moderate-to-severe hidradenitis suppurativa in two randomised trials.
Learn More >